- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Samsung Gets FDA Nod for Versatile V7 Ultrasound System
Offering uniform high-resolution images through a combination of beamforming and enhanced image processing, the new ultrasound platform reportedly has an array of diagnostic features ranging from cardiovascular applications to breast lesion assessment.
The Food and Drug Administration (FDA) has granted 510(k) clearance to the V7 Ultrasound system, which provides enhanced, high-resolution imaging for a variety of clinical applications Including cardiovascular and breast imaging, according to Samsung, the manufacturer of the device.
Samsung noted the increased resolution and clarity of imaging with the V7 Ultrasound system stems from Crystal Architecture™, which includes the use of S-Vue Single Crystal Transducers™ and proprietary beamforming (CrystalBeam™) and image processing technologies (CrystalLive™).
The ultrasound platform has a variety of specialized clinical features including the artificial intelligence (AI)-enabled UterineAssist™, which provides automated measurements of the uterus; 2D Follicle™, which allows automated measurements of follicles for gynecologic exams; and S-Detect™ for Breast, which assesses breast lesions and applies appropriate BI-RADS ATLAS info to reporting.
“There is a continued demand on imaging professionals to deliver high-quality results in an efficient amount of time without compromising patient care,” noted David Legg, vice president and head of Boston Imaging, the United States headquarters for Samsung’s digital radiography and ultrasound business. “We’re proud to help address this by supplying one more solution that helps make clinical assessments effortless and treatment precise.”
Other clinical measurement tools with the V7 Ultrasound include ArterialAnalysis, which detects functional blood vessel changes; AutoIMT+, which measures the intima-media thickness of the posterior and anterior walls of the common carotid; and AutoEF, which assesses potential ejection fraction through different measurements in the left ventricle, according to Samsung.
Samsung said the V7 Ultrasound device also enables clinicians to get better image quality through technologies such as HQ-Vision™ and ClearVision. The company explained that HQ-Vision reportedly mitigates contributing characteristics to blurry imaging and ClearVision reduces noise with enhanced edge contrast of two-dimensional images.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
